Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR-iNK 007
- Development stage
- Preclinical
- Lead developer
- ThinkingBiomed
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
CAR-iNK 007 is an induced pluripotent stem cell (iPSC)-derived chimeric antigen receptor (CAR) natural killer (NK) cell therapy under development by ThinkingBiomed. The candidate is engineered to express a CAR to recognize tumor-associated antigens and mediate cytotoxic killing of malignant cells. As an iPSC-derived product, it is intended to provide an "off-the-shelf" allogeneic treatment option, potentially overcoming the limitations of patient-specific autologous therapies. It is currently in the early research/preclinical stage for the treatment of various solid and hematological cancers, including lung cancer, liver cancer, colorectal cancer, and B-cell lymphoma. The specific antigen target for CAR-iNK 007 has not been publicly disclosed by the developer.
- Other names
- CAR-iNK 007CAR-iNK007CAR-iNK-007
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on CAR-iNK 007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAR-iNK 007.